Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
96 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2015', provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cognitive Impairment Associated With Schizophrenia (CIAS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cognitive Impairment Associated With Schizophrenia (CIAS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Cognitive Impairment Associated With Schizophrenia (CIAS) Overview 9 Therapeutics Development 10 Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview 10 Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS) - Comparative Analysis 11 Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics under Development by Companies 12 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Cognitive Impairment Associated With Schizophrenia (CIAS) - Products under Development by Companies 18 Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development 20 AbbVie Inc. 20 Amarantus Bioscience Holdings, Inc. 21 Avineuro Pharmaceuticals, Inc. 22 CoMentis, Inc. 23 Eli Lilly and Company 24 FORUM Pharmaceuticals Inc. 25 H. Lundbeck A/S 26 Intra-Cellular Therapies, Inc. 27 Iproteos S.L. 28 Merck & Co., Inc. 29 Mithridion, Inc. 30 Mnemosyne Pharmaceuticals, Inc. 31 Novartis AG 32 Pfizer Inc. 33 Saniona AB 34 Siena Biotech S.p.A. 35 SK Biopharmaceuticals Co., Ltd. 36 Sunovion Pharmaceuticals Inc. 37 Takeda Pharmaceutical Company Limited 38 Upsher-Smith Laboratories, Inc. 39 Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment 40 Assessment by Monotherapy Products 40 Assessment by Target 41 Assessment by Mechanism of Action 43 Assessment by Route of Administration 45 Assessment by Molecule Type 46 Drug Profiles 48 A-431404 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 ABT-126 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 AN-761 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 AQW-051 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 AUT-1 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 AVL-3288 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 AVN-211 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 BNC-375 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 CDD-0304 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 DSP-3748 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 eltoprazine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 encenicline hydrochloride - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 erteberel - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 GTS-21 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 IPR-001 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 IPR-088 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 ITI-214 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 LUAF-64280 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 PNU-120596 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 roflumilast - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 SEN-15924 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 SKL-15508 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Small Molecule to Agonize Neuronal Acetylcholine Receptor Subunit Alpha-7 for Central Nervous System - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Small Molecule to Agonize NMDA2B for CIAS - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Small Molecules for Cognitive Impairment Associated with Schizophrenia - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 TAK-058 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Cognitive Impairment Associated With Schizophrenia (CIAS) - Recent Pipeline Updates 82 Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects 91 Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products 93 Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones 94 Featured News & Press Releases 94 Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia 94 Feb 19, 2013: Intra-Cellular Therapies Completes Phase I Single Rising Dose Trial Of Selective Phosphodiesterase 1 Inhibitor 94 Appendix 95 Methodology 95 Coverage 95 Secondary Research 95 Primary Research 95 Expert Panel Validation 95 Contact Us 96 Disclaimer 96
List of Tables Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H1 2015 10 Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Comparative Analysis, H1 2015 11 Number of Products under Development by Companies, H1 2015 13 Number of Products under Development by Companies, H1 2015 (Contd..1) 14 Comparative Analysis by Late Stage Development, H1 2015 15 Comparative Analysis by Clinical Stage Development, H1 2015 16 Comparative Analysis by Early Stage Development, H1 2015 17 Products under Development by Companies, H1 2015 18 Products under Development by Companies, H1 2015 (Contd..1) 19 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AbbVie Inc., H1 2015 20 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2015 21 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Avineuro Pharmaceuticals, Inc., H1 2015 22 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by CoMentis, Inc., H1 2015 23 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Eli Lilly and Company, H1 2015 24 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by FORUM Pharmaceuticals Inc., H1 2015 25 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by H. Lundbeck A/S, H1 2015 26 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Intra-Cellular Therapies, Inc., H1 2015 27 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Iproteos S.L., H1 2015 28 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Merck & Co., Inc., H1 2015 29 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Mithridion, Inc., H1 2015 30 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2015 31 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Novartis AG, H1 2015 32 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc., H1 2015 33 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Saniona AB, H1 2015 34 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Siena Biotech S.p.A., H1 2015 35 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 36 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Sunovion Pharmaceuticals Inc., H1 2015 37 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 38 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Upsher-Smith Laboratories, Inc., H1 2015 39 Assessment by Monotherapy Products, H1 2015 40 Number of Products by Stage and Target, H1 2015 42 Number of Products by Stage and Mechanism of Action, H1 2015 44 Number of Products by Stage and Route of Administration, H1 2015 45 Number of Products by Stage and Molecule Type, H1 2015 47 Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics - Recent Pipeline Updates, H1 2015 82 Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H1 2015 91 Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects (Contd..1), H1 2015 92 Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, H1 2015 93
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.